A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

The UChicago Medicine team will be led by Odunsi as co-principal investigator and includes Christopher Weber, Savas Tay, and ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups, according to a new study. The ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca shared the topline result ... developed by Array BioPharma before AZ licensed the drug in 2003. The MEK 1/2 ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...